qax028
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00568503)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M2ANTAGONIST
CHRM2 antagonist
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- qax028
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01068613 | Phase 2 | Jan 1, 2010 | Novartis |
| NCT00568503 | Phase 1 | Oct 1, 2007 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 2 | 2007 |
1 organizations
Page 1 / 1